Published • loading... • Updated
Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism
Summary by Stocks Down Under
1 Articles
1 Articles
Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism
Cyclopharm (ASX:CYC) is a rare species – an ASX stock that is approved in the US market. However, its share price has gone in the opposite direction. Cyclopharm has not had as fast an uplift as other companies have had and still makes most of its sales from other jurisdictions. A lawsuit from 4D Medical…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium